Please login to the form below
Tcelna
This page shows the latest Tcelna news and features for those working in and with pharma, biotech and healthcare.
Merck KGaA drops Ono-partnered multiple sclerosis drug
It also has a licensing deal in place for Tcelna (imilecleucel-T), a personalised treatment for secondary-progressive MS developed by Opexa Therapeutics that is in phase IIb testing with
Latest news
-
Currencies hit Merck Serono sales but firm says it is 'on course'
Overall groups sales down to €2.84bn for second quarter of 2013
-
Merck KGaA to meet 2014 financial targets one year early
and recently-licensed MS drug Tcelna (imilecleucel-T) following the decision to drop brain and lung cancer prospect cilengitide from development in the first quarter.
-
Merck KGaA and Opexa enter MS deal
Will develop personalised T-cell based medicine Tcelna. Merck KGaA has agreed a deal with Opexa Therapeutics to develop and commercialise a new personalised treatment for multiple sclerosis (MS). ... During the SPMS trial, patients undergo two annual
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Pharma deals during February 2013
sales. In the other option deal, Merck Serono has acquired an option over Opexa Therapeutics' phase IIb Tcelna (imilecleucel-T) vaccine for MS (for all territories except Japan). ... Tcelna is being developed as a personalised therapy specifically
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Medical Writer/ Senior Medical Writer opportunities – Macclesfie...
-
competitive salary and benefits package
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
- Pharma Brand Planners’ Blog (Part 2)
- The social dilemma: is it time for pharma to join the party?
- GCI Health continues to go from strength to strength, with significant new hires
- Sanofi/Regeneron’s Dupixent successor underwhelms in phase 2
- Faced with regulator’s merger concerns, BMS want to offload Otezla
- MIT reveals new pill to deliver insulin
PMHub
Complete HealthVizion
Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...
Latest intelligence
- The social dilemma: is it time for pharma to join the party?
- Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
- MIT reveals new pill to deliver insulin
- A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
- 25 Women Leaders in UK Healthcare
- Women trailblazers helping to shape the future of healthcare (Part 1)...
Quick links
Infographics
